On June 24, 2026, Xella Health launched as an AI-powered precision-health platform designed to detect more than 130 conditions specific to female biology — including PMOS (the newly renamed polycystic ovary syndrome), endometriosis, Hashimoto's, PMDD, and perimenopause timelines — by sequencing biomarker data across genomics, proteins, and hormones. Members complete an onboarding questionnaire, schedule a blood draw through partner labs such as Quest or Labcorp, and receive an AI-generated probability risk profile across the 130+ conditions, which is then translated into a personalized healthcare roadmap and reviewed with a certified clinician through the platform's telehealth layer.

Why It Matters

Xella lands in a femtech moment defined by two converging trends: the migration of women's health from consumer wellness apps toward clinically rigorous, lab-backed diagnostics, and a wave of multi-omic "precision health" startups applying genomic and proteomic sequencing to chronic, under-diagnosed conditions. Its $499 membership and Mammoth Biosciences pedigree signal an attempt to professionalize a category long stuck in cycle-tracking and self-report. The platform's explicit adoption of "PMOS" — the May 2026 Lancet rebrand of PCOS — also shows how quickly diagnostic startups are aligning with emerging clinical consensus. For investors and clinicians, Xella is a test of whether women will pay out of pocket for predictive, multi-omic screening, and whether AI risk-profiling can deliver on the promise of closing the gender diagnostic gap without overdiagnosis.

The company was founded by Kelly Lacob, Adriana Dantas, and Dr. Jesus Ching — all three alumni of CRISPR-diagnostics company Mammoth Biosciences. Xella pairs multi-omic testing processed through its own CLIA-certified and CAP-accredited lab with personalized telehealth care and longitudinal tracking. Annual membership runs $499 (HSA/FSA eligible), with additional testing available at extra cost. The startup is advised by Dr. Allison Kurian, director of Stanford's Women's Clinical Cancer Genetics Program, and Dr. Lynn Westphal, chief medical officer of Kindbody, among others drawn from Mammoth, Roche, and GRAIL.

Lacob framed the launch around the diagnostic gap that has dogged women's health for decades. "Women have been trapped in a diagnostic dark age experiencing debilitating symptoms routinely dismissed by the healthcare system," she said, citing the roughly four-year lag in diagnosis women face relative to men for the same conditions. Xella positions itself not as another symptom-logging app but as an upstream diagnostic engine meant to surface risk before symptoms are dismissed.

Sources

Update — 2026-06-29

{Initial entry — story first created.}